OncoMatch/Clinical Trials/NCT06623656
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC
Is NCT06623656 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Platinum based chemotherapy for carcinoma, non-small-cell lung.
Treatment: Cemiplimab · Platinum based chemotherapy — The goal of this clinical trial is to learn if Cemiplimab with chemotherapy or Cemiplimab with stereotactic body radiation therapy (SBRT) works as treatment for stages IB, II, and III (N2) Non-Small Cell Lung Cancer (NSCLC). Before surgery to remove their lung cancer, participants will take: 1. Cemiplimab with chemotherapy (Arm A) every 3 weeks for up to 3 doses, OR 2. Cemiplimab every 3 weeks for up to 3 doses with SBRT (Arm B). SBRT will be given on day 1 before taking cemiplimab, then SBRT alone on day 2 and day 3. Four to 12 weeks following surgery, participants in both Arm A and Arm B will receive treatment with cemiplimab for one year.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
No known EGFR mutations
Required: ALK wild-type
No known ... ALK fusions
Required: PD-L1 (CD274) expression (known PD-L1 expression (no threshold specified))
Known PD-L1 expression
Disease stage
Required: Stage IB (T2AN0), II, III(N2)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5 x10^3/uL; Platelets ≥75 x10^3/uL; Hemoglobin ≥9 g/dL
Kidney function
Serum creatinine ≤1.5 X ULN OR calculated CrCl ≥50 ml/min (Cockcroft-Gault)
Liver function
Serum total bilirubin ≤1.5 X ULN (≤3x ULN if Gilbert's Syndrome); AST/ALT ≤3 X ULN
Adequate organ and bone marrow function as defined below: ANC ≥1.5 x10(3)/uL; Platelets ≥75 x10(3)/uL; Hemoglobin ≥9 g/dL; Serum creatinine ≤1.5 X ULN OR calculated CrCl ≥50 ml/min (using the Cockcroft-Gault formula). Serum total bilirubin ≤1.5 X ULN, except in patients with clinically documented Gilbert's Syndrome where ≤3x the ULN is permitted; AST/ALT ≤3 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Weill Cornell Medicine · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify